KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Working Capital Changes (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Other Working Capital Changes for 17 consecutive years, with -$41.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes fell 153.8% year-over-year to -$41.0 million, compared with a TTM value of -$8.9 million through Dec 2025, down 335.34%, and an annual FY2025 reading of -$8.9 million, down 335.34% over the prior year.
  • Other Working Capital Changes was -$41.0 million for Q4 2025 at Biomarin Pharmaceutical, down from $17.0 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $36.0 million in Q1 2023 and bottomed at -$42.8 million in Q1 2021.
  • Average Other Working Capital Changes over 5 years is $382000.0, with a median of $6.1 million recorded in 2023.
  • The sharpest move saw Other Working Capital Changes tumbled 499.78% in 2022, then soared 349.39% in 2023.
  • Year by year, Other Working Capital Changes stood at -$2.7 million in 2021, then crashed by 499.78% to -$16.4 million in 2022, then surged by 44.73% to -$9.1 million in 2023, then crashed by 78.5% to -$16.2 million in 2024, then plummeted by 153.8% to -$41.0 million in 2025.
  • Business Quant data shows Other Working Capital Changes for BMRN at -$41.0 million in Q4 2025, $17.0 million in Q3 2025, and $8.8 million in Q2 2025.